Bioequivalence and Pharmacokinetic Comparison of Generic Versus Branded Extended-Release Metformin Formulations

Authors

  • Smit D Department of Pharmaceutics, Erasmus University Rotterdam, Rotterdam, Netherlands Author
  • Kovac L Department of Clinical Pharmacology, University of Split, Split, Croatia Author
  • Nilsson G Department of Pharmacokinetics, Karolinska Institute, Stockholm, Sweden Author

DOI:

https://doi.org/10.5281/zenodo.22664506

Keywords:

bioequivalence, extended-release metformin, generic substitution, pharmacokinetics, dissolution testing

Abstract

Background: Extended-release (ER) metformin formulations reduce the gastrointestinal intolerance associated with
immediate-release dosing, but generic ER products must independently demonstrate bioequivalence to the branded reference
product before substitution can be assumed safe and effective. Objective: To evaluate the pharmacokinetic and dissolution
equivalence of a generic extended-release metformin hydrochloride 500 mg tablet relative to its branded reference product, and to
consider the clinical implications of generic substitution for chronic diabetes management. Methods: A randomized, open-label,
single-dose, two-treatment, two-period, two-sequence crossover pharmacokinetic study was conducted in healthy adult volunteers
under fasting and fed conditions, with Cmax, AUC0-t, and AUC0-inf compared using the standard 90% confidence interval,
80.00-125.00% average bioequivalence acceptance criteria specified by FDA and EMA guidance. In vitro dissolution profiles were
compared across three physiological pH conditions using the similarity factor f2. Findings: The 90% confidence intervals for Cmax,
AUC0-t, and AUC0-inf fell within the 80.00-125.00% acceptance range under both fasting and fed conditions, median Tmax differed
modestly but not to a clinically meaningful degree, and dissolution profiles were similar (f2 >= 50) across all pH conditions tested,
with the narrowest margin observed at pH 6.8. No clinically significant differences in adverse events, including gastrointestinal
tolerability, were observed between formulations. Conclusions: The generic extended-release metformin tablet met regulatory
bioequivalence standards, supporting its therapeutic interchangeability with the branded product. Residual uncertainty around
chronic dosing, patient populations with reduced renal clearance, and within-subject variability in release kinetics warrants
ordinary clinical vigilance, rather than additional pre-approval testing burden, when patients are switched between formulations.

References

Rena G, Hardie DG, Pearson ER (2017) The mechanisms of action of metformin. Diabetologia, 60(9):1577-1585, DOI:10.1007/s00125-017-4342-z.

Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ (2004) Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion, 20(4):565-572, DOI:10.1185/030079904125003278.

Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH (2008) Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA, 300(21):2514-2526, DOI:10.1001/jama.2008.758.

Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 12(3):413-420, DOI:10.1023/A:1016212804288.

Chen W, Desai D, Good D, Crison J, Timmins P, Paruchuri S, Wang J, Ha K (2016) Mathematical model-based accelerated development of extended-release metformin hydrochloride tablet formulation. AAPS PharmSciTech, 17(4):1007-1013, DOI:10.1208/s12249-015-0423-9.

Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH (2004) Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. European Journal of Pharmaceutical Sciences, 22(4):297-304, DOI:10.1016/j.ejps.2004.03.016.

Metry M, Shu Y, Abrahamsson B, Christofoletti R, Dressman JB, Groot DW, Parr A, Langguth P, Shah VP, Tajiri T, Mehta MU, Polli JE (2021) Biowaiver monographs for immediate release solid oral dosage forms: metformin hydrochloride. Journal of Pharmaceutical Sciences, 110(4):1513-1526, DOI:10.1016/j.xphs.2021.01.011.

Zhou Z, Wang C, Li M, Lan Q, Yu C, Yu G, Xia Y, Chen H, Zhang X (2021) In vitro dissolution and in vivo bioequivalence evaluation of two metformin extended-release tablets. Clinical Pharmacology in Drug Development, 10(4):414-419, DOI:10.1002/cpdd.857.

Hu C, Pei T, Li D, Zhou D, Zhang L (2022) Bioequivalence of China- and Germany-manufactured metformin extended-release tablets under fed and fasted conditions in healthy volunteers: a randomized, open-label, 2-way crossover study. Clinical Pharmacology in Drug Development, 11(12):1430-1439, DOI:10.1002/cpdd.1158.

Verbeeck RK, Musuamba FT (2012) The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. Journal of Pharmacy & Pharmaceutical Sciences, 15(3):376-388, DOI:10.18433/j3vc8j.

Nocera D, Forastiero G, Logreco A, Proietti A, Galluccio A, Lunghi C, Poluzzi E, De Ponti F (2025) Toward the harmonization of bioequivalence guidelines in Europe: commentary on the state of the art and future priorities under ICH M13A for immediate-release oral forms. British Journal of Clinical Pharmacology, DOI:10.1002/bcp.70429.

Sun ML, Liu C, Bai HH, Wei YL, Zhang W, Liu HJ, Li YJ, Liu L, Wang Y, Tong YX, Gao Q, Liu QY, Wang X (2022) Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke and Glucophage-XR) in healthy Chinese volunteers: a randomized phase I clinical trial. Annals of Medicine, 54(1):2626-2635, DOI:10.1080/07853890.2022.2125574.

Lim PC, Lim SL, Khaw CH, Lim YL, Hassali MA, Chong CP (2019) Evaluation of glycaemic control comparing originator versus generic fixed-dose glibenclamide/metformin tablet among diabetes mellitus patients in an outpatient clinic. Journal of Pharmacy Practice and Research, 49(3):224-233, DOI:10.1002/jppr.1494.

Chen HY, Chang HY, Lang HC, Lin HW, Chiu YW (2014) Effects of hospital generic drug substitution on diabetes therapy. Patient Preference and Adherence, 8:127-133, DOI:10.2147/PPA.S54917.

Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011) Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 50(2):81-98, DOI:10.2165/11534750-000000000-00000.

Ring A, Lang B, Kazaroho C, Labes D, Schall R, Schutz H (2019) Sample size determination in bioequivalence studies using statistical assurance. British Journal of Clinical Pharmacology, 85(10):2369-2377, DOI:10.1111/bcp.14055.

Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino LA, Avorn J, Campbell EG (2016) Variations in patients' perceptions and use of generic drugs: results of a national survey. Journal of General Internal Medicine, 31(6):609-614, DOI:10.1007/s11606-016-3612-7.

Anim Anno K, Mina M, Zhang Z, Zhang L, Jiang W (2025) Analysis on the impact of U.S. FDA's narrow therapeutic index bioequivalence criteria on generic drug applications. The AAPS Journal, 27(1):42, DOI:10.1208/s12248-025-01020-1.

Seuring T, Archangelidi O, Suhrcke M (2015) The economic costs of type 2 diabetes: a global systematic review. PharmacoEconomics, 33(8):811-831, DOI:10.1007/s40273-015-0268-9.

Sacks NC, Burgess JF, Cabral HJ, Pizer SD, McDonnell ME (2013) Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries. Journal of General Internal Medicine, 28(7):876-885, DOI:10.1007/s11606-013-2342-3.

Downloads

Published

2024-12-22